<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045682</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0186C</org_study_id>
    <secondary_id>NCI-2012-02493</secondary_id>
    <secondary_id>CDR0000257039</secondary_id>
    <secondary_id>GOG-0186C</secondary_id>
    <secondary_id>GOG-0186C</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00045682</nct_id>
  </id_info>
  <brief_title>CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent&#xD;
      or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the antitumor activity of polyglutamate paclitaxel (CT-2103) as third-line&#xD;
      treatment for patients with recurrent or persistent ovarian epithelial or primary peritoneal&#xD;
      cancer.&#xD;
&#xD;
      II. Determine the nature and degree of toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">July 15, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and duration of objective response</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of observed adverse effects</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of progression-free interval</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in objective response</measure>
    <time_frame>Baseline to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in observed adverse effects</measure>
    <time_frame>Baseline to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (polyglutamate paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Poliglumex</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (polyglutamate paclitaxel)</arm_group_label>
    <other_name>CT-2103</other_name>
    <other_name>Paclitaxel Polyglutamate</other_name>
    <other_name>PG-TXL</other_name>
    <other_name>Xyotax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed recurrent or persistent ovarian epithelial cancer or primary&#xD;
             peritoneal cancer after second-line therapy&#xD;
&#xD;
               -  Received 1 prior platinum-based first-line chemotherapy regimen and 1 prior&#xD;
                  second-line (non-platinum, non-taxane) chemotherapy regimen&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  At least 1 target lesion that has not previously been irradiated&#xD;
&#xD;
          -  Ineligible for a higher priority GOG protocol (if one exists)&#xD;
&#xD;
          -  Ineligible for the currently active phase II cytotoxic protocol for platinum-resistant&#xD;
             disease&#xD;
&#xD;
          -  Performance status - GOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  PT or PTT less than ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No uncompensated congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No sensory or motor neuropathy greater than grade 1&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 3 weeks since prior biological therapy or immunotherapy directed at the&#xD;
             malignancy&#xD;
&#xD;
          -  No prior polyglutamate paclitaxel (CT-2103)&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy directed at the malignancy&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  At least 3 weeks since other prior therapy directed at the malignancy&#xD;
&#xD;
          -  No prior therapy for another malignancy that would preclude this study&#xD;
&#xD;
          -  No concurrent amifostine or other protective reagents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Paclitaxel poliglumex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

